Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2018

Amphastar Pharmaceuticals (AMPH) PT Lowered to $22 at Needham & Company

August 9, 2018 1:38 PM EDT

Needham & Company lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $22.00 (from $24.00) while maintaining a Buy rating.

Analyst Serge Belanger remains positive as the recent approval of generic Isuprel, along with medroxyprogesterone and neostigmine will continue driving growth in... More

Amphastar Pharma (AMPH) Misses Q2 EPS by 4c

August 8, 2018 4:13 PM EDT

Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $71 million versus the consensus estimate of $62.9 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

... More